NasdaqGS:ALNYBiotechs
How New Vutrisiran Outcomes and Zilebesiran Safety Data Will Impact Alnylam Pharmaceuticals (ALNY) Investors
Alnylam Pharmaceuticals recently reported extensive new clinical and real-world data for its cardiovascular portfolio, highlighting vutrisiran’s impact in transthyretin-mediated amyloidosis with cardiomyopathy and pooled Phase 2 safety results for investigational hypertension therapy zilebesiran, presented at the American College of Cardiology’s 2026 scientific meeting.
The depth of HELIOS-B outcomes, quality-of-life findings, and long-term real-world use of vutrisiran, together with...